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Reference values in lung function testing: All for one and one for all?
Lung function tests are used in clinical practice to detect “abnormality” against a back-
ground of “normal” function. “Abnormality” may be determined either by (i) detection 
of some discrete abnormality (eg, the shape of the ﬂ  ow volume loop) or (ii) by the use 
of reference values to show a relative change in values (eg, forced expiratory volume 
in one second [FEV1] = 30% of predicted) or (iii) relative differences in several values 
(eg, obstructive spirometry but relatively raised lung volumes). Lung function tests 
are also used to longitudinally monitor therapy or disease progression.
Using reference values to produce “percent of predicted” measures can lead to serious 
misinterpretation of results and subsequent inappropriate diagnosis and treatment. It has 
been recognized in Europe and North America for over 20 years (Quanjer et al 1983, 
1993; Pellegrino et al 2005) that using “percent of predicted” is scientiﬁ  cally unsound 
and should therefore be replaced by or used alongside “standardized residuals” which are 
a more scientiﬁ  cally robust way to express results. Knowing that a patient’s FEV1 value 
is below 1.64 standardized residuals gives more conﬁ  dence when interpreting a respira-
tory disorder. Taken together with the “percent of predicted” values the two ﬁ  gures can 
help to indicate the “severity” of abnormality without falling into the trap of the reference 
equations producing “false positives”, particularly in elderly patients (Miller 2007). 
Traditionally the AARC/ATS guidelines have recommended that utilization of 
reference values from a variety of populations should be veriﬁ  ed in local healthy 
nonsmoking subjects to determine their “local best ﬁ  t” reference values. In Europe, 
the adoption of a generic and averaged “euro-lung” set of reference values (Quanjer 
et al 1983. 1993) has been recommended with some ethnic correction factors for non-
Caucasian subjects. Clearly neither of these methods is ideal or without signiﬁ  cant 
errors. Whilst these ethnic correction factors were probably ﬁ  nancially expedient in 
the 1980s, it is clearly unacceptable to continue this practice today, and more reference 
value studies on most of the major races populating Europe needs undertaking. 
The greatest problem for introducing new reference values is deciding that they are 
“better” than previously used values. “Better” usually means that the normal distribu-
tion of the values is “tightened” by the improved selection of control subjects criteria, 
the use of improved quality spirometry (performance or equipment) or a greater number 
of subjects being included. The dilemma is deciding which set of reference values is 
“the gold standard” and whether older values should be replaced.
In this issue Sood and colleagues (2007) compare new reference values 
(NHANES III) (Hankinson et al 1999) from a population of non-Hispanic Caucasians 
living in the USA with the traditional values used by AARC/ATS for over 30 years 
(Kory et al 1961; Knudson et al 1976, 1983; Morris et al 1971, 1973; Morris 1976; 
Crapo et al 1982). Data from two populations of restrictive and obstructive patients are 
used to highlight the lack of agreement between sets of reference values in detecting 
“abnormality”, but good agreement when it comes to “severity” of disease. The authors 
cite the new ATS/ERS recommendation (Pellegrino et al 2005) as the driver to adopt 
NHANES III values, and highlight the consequences which may become costly in 
terms of confusion, misdiagnosis, and the practicalities of respiratory specialists and 
equipment manufacturers adopting the new reference values.  
The study begs the question whether the European (ECSC) reference values 
(Quanjer et al 1983, 1993) should themselves be updated for European populations. International Journal of COPD 2007:2(3)  190
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There needs to be an examination of whether the costs of 
developing what may amount to perhaps a subtle “intel-
lectual” change will actually make any signiﬁ  cant clinical 
difference when there are far more fundamental questions 
to answer with limited ﬁ  nancial resources. The effect on the 
burden of lung disease must be economically beneﬁ  cial to 
make such a fundamental change worthwhile. 
Whilst reference values are an important issue, they need to 
be considered with respect to other potential errors in lung func-
tion testing. For example, in primary care spirometry the largest 
errors are the poor quality of the tests performed which are often 
a direct result of poor training and support (Kaminsky et al 2005; 
Raghunath et al 2006; Tinkelman et al 2006; Miravitiles et al 
2007). Growing evidence indicates that equivalence in spirom-
etry only occurs between “lab and ofﬁ  ce” when an adequate 
training and mentoring programme is in place in primary care 
(Eaton et al 1999; Upton et al 2000; Johansen 2007).
Arguably the best way to monitor lung function for both 
the individual and the population as a whole is to adopt the 
“lung health” approach to respiratory healthcare. All adults 
at 25 years of age (ie, when lung growth is complete) (Sherill 
et al 1989), should have their spirometry measured accurately 
by trained and experienced healthcare professionals with qual-
ity-assured spirometers. This benchmark (similar to blood 
pressure monitoring) can help to establish “abnormality” from 
“normality” in an individual against reference values. It may 
then be possible to distinguish which individuals have a rela-
tive reduction in lung function. These susceptible individuals 
can then be monitored regularly (probably each decade) to see 
how much capacity they have left before respiratory disease 
causes major disability or morbidity. The concept of “loss 
of functional units on the road to death” has been described 
eloquently by Miller and colleagues (2005a, 2005b).
The data from such a lung health study like NHANES III 
can also be collected nationally to provide better reference val-
ues and monitor the lung health of the nation and evaluate the 
intervention of therapies and behavioral changes (new guide-
lines, smoking cessation, etc.). The savings from detecting early 
disease and decreasing the burden of lung disease in the elderly 
should offset any ﬁ  nancial pressures from the implementation of 
a lung health study. However, this has to be seen as a long term 
strategy in health economics and not a short term “quick ﬁ  x”. 
Sood and colleagues (2007) have boldly addressed the 
issue of differences in reference values and their implications 
for healthcare. This article will undoubtedly generate more 
discussion, further consideration, and careful implementation 
before the NHANES III data (or any other new reference 
values) are widely adopted. 
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